Oxytocin treatment in children with Prader–Willi syndrome: A double-blind, placebo-controlled, crossover study

American Journal of Medical Genetics, Part A

Volumn 173, Issue 5, 2017, Pages 1243-1250

  Miller, Jennifer L ^a   Tamura, Roy ^b   Butler, Merlin G ^c   Kimonis, Virginia ^d   Sulsona, Carlos ^a   Gold, June Anne ^e   Driscoll, Daniel J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hyperphagia; oxytocin; Prader Willi syndrome

Indexed keywords

GLUCOSE; OXYTOCIN; PLACEBO; POTASSIUM; SODIUM;

ABERRANT BEHAVIOR CHECKLIST; ANXIETY DISORDER; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; COMPULSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPHAGIA QUESTIONNAIRE; LOW DRUG DOSE; MACULOPAPULAR RASH; MALE; MULTICENTER STUDY; NOSE IRRITATION; POPULATION RESEARCH; POTASSIUM BLOOD LEVEL; PRADER WILLI SYNDROME; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPETITIVE BEHAVIOR SCALE REVISED; SKIN PAIN; SOCIAL RESPONSIVENESS SCALE; SOCIALIZATION; SODIUM BLOOD LEVEL; TOTAL QUALITY MANAGEMENT; BLOOD; PATHOLOGY; PRADER-WILLI SYNDROME; PRESCHOOL CHILD; QUALITY OF LIFE; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OXYTOCIN; POTASSIUM; PRADER-WILLI SYNDROME; QUALITY OF LIFE; SODIUM; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85016717611     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.38160     Document Type: Article

References (33)

1. Bachner-Melman, R., & Ebstein, R. P. (2014). The role of oxytocin and vasopressin in emotional and social behaviors. Handbook of Clinical Neurology, 124, 53–68.
2. Bittel, D. C., Kibiryeva, N., Sell, S. M., Strong, T. V., & Butler, M. G. (2007). Whole genome microarray analysis of gene expression in Prader-Willi syndrome. American Journal of Medical Genetics Part A, 143A(5), 415–421.
3. Buiting, K., Cassidy, S. B., Driscoll, D. J., Gillessen-Kaesbach, G., Kanber, D., Tauber, M., … Horsthemke, B. (2014). Clinical utility gene card for: Prader-Willi Syndrome. European Journal of Human Genetics, 22(9), 66.
4. Bull, L. E., Oliver, C., Callaghan, E., & Woodcock, K. A. (2015). Increased exposure to rigid routines can lead to increased challenging behavior following changes to those routines. Journal of Autism and Developmental Disorder, 45(6), 1569–1578.
5. Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., … Reich, W. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorder, 33(4), 427–433.
6. Conti, F., Sertic, S., Reversi, A., & Chini, B. (2009). Intracellular trafficking of the human oxytocin receptor: Evidence of receptor recycling via a Rab4/Rab5 “short cycle”. American Journal of Physiology - Endocrinology and Metabolism, 296, E532–E542.
7. Dombret, C., Nguyen, T., Schakman, O., Michaud, J. L., Hardin-Pouzet, H., Bertrand, M. J., & De Backer, O. (2012). Loss of Maged1 results in obesity, deficits of social interactions, impaired sexual behavior and severe alteration of mature oxytocin production in the hypothalamus. Human Molecular Genetics, 21(21), 4703–4717.
8. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome. 2016. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2016.
9. Dykens, E. M., Maxwell, M. A., Pantino, E., Kossler, R., & Roof, E. (2007). Assessment of hyperphagia in Prader-Willi syndrome. Obesity (Silver Spring), 15(7), 1816–1826.
10. Einfeld, S. L., Smith, E., McGregor, I. S., Steinbeck, K., Taffe, J., Rice, L. J., … Guastella, A. J. (2014). A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. American Journal of Medical Genetics Part A, 164A(9), 2232–2239.
11. Francis, S. M., Sagar, A., Levin-Decanini, T., Liu, W., Carter, C. S., & Jacob, S. (2014). Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders. Brain Research, 1580, 199–218.
12. Goldstone, A. P., Holland, A. J., Butler, J. V., & Whittington, J. E. (2012). Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. International Journal of Obesity, 36(12), 1564–1570.
13. Harony-Nicolas, H., Mamrut, S., Brodsky, L., Shahar-Gold, H., Barki-Harrington, L., & Wagner, S. (2014). Brain region-specific methylation in the promoter of the murine oxytocin receptor gene is involved in its expression regulation. Psychoneuroendocrinology, 39, 121–131.
14. Huang, H., Michetti, C., Busnelli, M., Managò, F., Sannino, S., Scheggia, D., … Papaleo, F. (2014). Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology, 39(5), 1102–1114.
15. Insel, T. R. (2010). The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behavior. Neuron, 65(6), 768–779.
16. Johnson, L., Manzardo, A. M., Miller, J. L., Driscoll, D. J., & Butler, M. G. (2016). Elevated plasma oxytocin levels in children with Prader-Willi syndrome compared with healthy unrelated siblings. American Journal of Medical Genetics Part A, 170(3), 594–601.
17. Koenig, K., Klin, A., & Schultz, R. (2004). Deficits in social attribution ability in Prader-Willi syndrome. Journal of Autism and Developmental Disorder, 34(5), 573–582.
18. Lam, K. S., & Aman, M. G. (2007). The repetitive behavior scale-revised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorder, 37(5), 855–866.
19. Lancaster, G. A. (2015). Pilot and feasibility studies come of age! Pilot and Feasibility Studies, 1, 1.
20. Lancaster, G. A., Dodd, S. R., & Williamson, P. R. (2004). Design and analysis of pilot studies: Recommendations for good practice. Journal of Evaluation in Clinical Practice, 10(2), 307–312.
21. Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., … Guillon, G. (2012). Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. Journal of Neuroendocrinology, 24(4), 609–628.
22. McGrath, J. M. (2013). Not all studies with small samples are pilot studies. The Journal of Perinatal and Neonatal Nursing, 27, 281–283.
23. Meziane, H., Schaller, F., Bauer, S., Villard, C., Matarazzo, V., Riet, F., … Muscatelli, F. (2015). An early postnatal oxytocin treatment prevents social and learning deficits in adult mice deficient for magel2, a gene involved in Prader-Willi syndrome and autism. Biological Psychiatry, 78(2), 85–94.
24. Miller, J. L., Lynn, C. H., Driscoll, D. C., Goldstone, A. P., Gold, J. A., Kimonis, V., … Driscoll, D. J. (2011). Nutritional phases in Prader-Willi syndrome. American Journal of Medical Genetics Part A, 155A(5), 1040–1049.
25. Okamoto Y., Ishitobi M., Wada Y., & Kosaka H. (2016). The potential of nasal oxytocin administration for remediation of autism spectrum disorders. CNS Neurol Drug Targets, 15(5), 564–577.
26. Passoni, I., Leonzino, M., Gigliucci, V., Chini, B., & Busnelli, M. (2016). Carbetocin is a functional selective gq agonist that does not promote oxytocin receptor recycling after inducing β-Arrestin-Independent internalisation. Journal of Neuroendocrinology, 28(4).
27. Rice, L. J., & Einfeld, S. L. (2015). Cognitive and behavioural aspects of Prader-Willi syndrome. Current Opinion in Psychiatry, 28(2), 102–106.
28. Sala, M., Braida, D., Lentini, D., Busnelli, M., Bulgheroni, E., Capurro, V., … Chini, B. (2011). Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: A neurobehavioral model of autism. Biological Psychiatry, 69(9), 875–882.
29. Schaller, F., Watrin, F., Sturny, R., Massacrier, A., Szepetowski, P., & Muscatelli, F. (1995). A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. Human Molecular Genetics, 19(24), 4895–4905.
30. Swaab, D. F., Purba, J. S., & Hofman, M. A. (1995). Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: A study of five cases. The Journal of Clinical Endocrinology and Metabolism, 80(2), 573–579.
31. Tauber, M., Mantoulan, C., Copet, P., Jauregui, J., Demeer, G., Diene, G., … Thuilleaux, D. (2011). Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: A randomised placebo-controlled trial in 24 patients. Orphanet Journal of Rare Diseases, 6, 47.
32. Wigger, A., Sánchez, M. M., Mathys, K. C., Ebner, K., Frank, E., Liu, D., … Landgraf, R. (2004). Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: Critical role of vasopressin. Neuropsychopharmacology, 29(1), 1–14.
33. Yee J. R., Kenkel W. M., Frijling J. L., Dodhia S., Onishi K. G., Tovar S., … Carter CS. (2016). Oxytocin promotes functional coupling between paraventricular nucleus and both sympathetic and parasympathetic cardioregulatory nuclei. Hormones and Behavior, 80:82–91.